安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Consensus recommendations on the management of toxicity associated with . . .
The overarching goal of this project was to develop expert consensus recommendations specific to the assessment and management of CD3×CD20 BsAb–related adverse events (AEs)
- Prevalence of adverse events following bispecific antibody therapy in . . .
Treatment related adverse events (TRAE) include infections, cytokine release syndrome (CRS), neurotoxicity (ICANS) This meta-analysis was conducted to assess prevalence of TRAEs from prospective clinical trials that evaluated BsAb in R R NHL
- Diagnosis and management of bispecific T cell–engaging antibody . . .
This review was written by emergency medicine physicians in collaboration with oncologists who routinely administer BsAbs to provide guidelines and an overview on diagnosis, treatment, and management strategies for adverse events related to bispecific antibodies
- Bispecific antibody therapies - PMC
The scope of this article is to review hematological complications to bispecific antibody and bispecific-T-cell-engager (BiTE) treatment in hematologic malignancies, based on published trials and abstracts, and to propose some recommendations for their management
- Management of Toxicities After Bispecific Antibody Therapy in Non . . .
The information presented resulted in the development of toxicities management strategies and information relevant to the use of this novel therapy in the treatment of people with lymphoma
- Bispecific Antibodies and Antibody–Drug Conjugates in Relapsed . . .
The aim of this review is to explore actual therapies in relapsed refractory diffuse large B-cell lymphoma, focusing on bispecific antibodies and antibody–drug conjugates
- Prevalence of adverse events following bispecific antibody therapy in . . .
Treatment related adverse events (TRAE) include infections, cytokine release syndrome (CRS), neurotoxicity (ICANS) This meta-analysis was conducted to assess prevalence of TRAEs from prospective clinical trials that evaluated BsAb in R R NHL
- Best practices in expanding access to BISPECIFIC ANTIBODIES AND ADVERSE . . .
Examples of a few investigational BsAbs that engage T-cells include talquetamab for multiple myeloma, mosunetuzumab for non- Hodgkin’s lymphoma, and epcoritamab for diffuse large B-cell lymphoma 5
|
|
|